Search

Displaying results 1241 - 1250 of 6075 in total
  1. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

  2. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes. … [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.

  3. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    , while the existing tablet formulation remains indicated for patients aged six years and older. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.

  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  5. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting. … Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections [L2570], [L2571].

  6. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Etodolac

    go.drugbank.com/drugs/DB00749
    ApprovedInvestigationalVet approved

    It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

  8. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    that is less frequent than that for turoctocog alfa. … As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients

  9. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals … PHN can last for days, months, or even years following resolution of shingles.

    Categories: Antiinfectives for Systemic Use
  10. Drug

    Norfloxacin

    go.drugbank.com/drugs/DB01059
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use